ZGNX - Zogenix: Fintepla Late June PDUFA Date - A Catalyzing Moment For Its Shares
Zogenix (ZGNX) pulled back hard in late February of this year, touching a three-year low on Fintepla® Phase 3 data for Lennox-Gastaut syndrome, "LGS", which met the trial's objectives, but were not as good as some expected given the drug's impressive efficacy in Dravet syndrome,"DS". The stock took a second hit when the FDA requested additional data to complete the regulatory review for Fintepla in DS. While the stock has rebounded somewhat from its lows during the COVID-19 pandemic outbreak, opportunity remains after Zogenix provided regulators with the requested additional data, and